Ticlopidine and clopidogrel

Circulation

Volumn 100, Issue 15, 1999, Pages 1667-1672

  Quinn, Martin J ^a   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Antiplatelets; Clopidogrel; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CARBAMAZEPINE; CLOPIDOGREL; PHENYTOIN; THEOPHYLLINE; TICLOPIDINE; WARFARIN;

ARTICLE; BONE MARROW APLASIA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY STENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; NEUTROPENIA; PERIPHERAL VASCULAR DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS;

EID: 0032879820     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.15.1667     Document Type: Article

References (66)

1. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996; 348:1329-1339.
2. Meyers KM, Holmsen H, Seachord CL. Comparative study of platelet dense granule constituents. Am J Physiol. 1982;243:R454-R461.
3. Gardner A, Jonsen J, Laland S, Hellem A, Owren P. Adenosine diphosphate in red blood cells as a factor in the adhesiveness of human blood platelets. Nature. 1961;192:531-532.
4. Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther. 1994;64:445-475.
5. Jin J, Daniel J, Kunapuli S. Molecular basis for ADP induced platelet aggregation: the P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 1998; 273:2030-2034.
6. Sun B, Li J, Okahara K, Kambayashi J. P2X1 purinoceptor in human platelets: molecular cloning and functional characterization after heterologous expression. J Biol Chem. 1998;273:11544-11547.
7. Savi P, Boraia J, Salel V, Delfaud M, Herbert JM. Characterization of P2X1 purinoreceptors on rat platelets: effect of clopidogrel. Br J Haematol. 1997;98:880-886.
8. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood. 1998;92:152-159.
9. Leon C, Hechler B, Vial C, Leray C, Cazenave JP, Cachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett. 1997;403:26-30.
10. Savi P, Laplace MC, Herbert JM. Evidence for the existence of two different ADP-binding sites on rat platelets. Thromb Res. 1994;76: 157-169.
11. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 1998;422:291-295.
12. Daniel J, Dangelmaier C, Jin J, Ashby B, Smith J, Kunapuli S. Molecular basis for ADP-induced platelet activation: evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273:2024-2029.
13. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA. 1998;95:8070-8074.
14. Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP, Maffrand JP. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost. 1991;65:186-190.
15. Geiger J, Brich J, Honig-Liedl P. Thienopyridine-based antiplatelet drugs inhibit ADP effects on prostaglandin-stimulated, cAMP/PKA-mediated phosphorylation of the cytoskeletal protein VASP in human platelets. Circulation. 1998;98(suppl I):I-595. Abstract.
16. Gachet C, Savi P, Ohlmann P, Maffrand JP, Jakobs KH, Cazenave JP. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes: an effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemost. 1992;68:79-83.
17. Savi P, Pflieger AM, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis. 1996; 7:249-252.
18. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, Herbert JM. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313-317.
19. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Lovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest. 1985;75:328-338.
20. Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet. 1994;26:347-355.
21. Shah J, Fratis A, Ellis D, Murakami S, Teitelbaum P. Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J Clin Pharmacol. 1990;30:733-736.
22. Heptinstall S, May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost. 1995;74:1310-1315.
23. Chignard M, Lalau Keraly C, Delautier D, Sebag C, Bouloux C, Motte G, Benveniste J. Reduced sensitivity of human platelets to PAF-acether following ticlopidine intake. Haemostasis. 1989;19:213-218.
24. Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Mannucci PM. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost. 1991;66:694-699.
25. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost. 1996;76: 939-943.
26. Panak E, Blanchard J, Roe RL. Evaluation of the antithrombotic efficacy of ticlopidine in man. Agents Actions Suppl. 1984;15:148-166.
27. Coukell AJ, Markham A. Clopidogrel. Drugs. 1997;54:745-750.
28. McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs. 1990;40:238-259.
29. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1: 1215-1220.
30. Gill S, Majumdar S, Brown NE, Armstrong PW. Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. Can J Cardiol. 1997;13:909-913.
31. Love B, Biller J, Gent M. Adverse haematological effects of ticlopidine: prevention, recognition and management. Drug Safety. 1998;19:89-98.
32. Bennett C, Weinberg P, Rozenberg-Ben-Dror K, Yamold P, Kwaan H, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med. 1998;128:541-544.
33. Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura. N Engl J Med. 1997;337:1245. Letter.
34. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet. 1991;337: 774-776.
35. Yim HB, Lieu PK, Choo PW. Ticlopidine induced cholestatic jaundice. Singapore Med J. 1997;38:132-133.
36. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321: 501-507.
37. Rupprecht HJ, Darius H, Borkowski U, Voigtlander T, Nowak B, Genth S, Meyer J. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation. 1998;97: 1046-1052.
38. Herbert J, Dol F, Bernat A, Falotico R, Lale A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998;80: 512-518.
39. Umemura K, Kondo K, Ikeda Y, Nakashima M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost. 1997;78: 1381-1384.
40. Rindone JP, Bryan GN. Phenytoin toxicity associated with ticlopidine administration. Arch Intern Med. 1996;156:1113. Letter.
41. Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther. 1997;62:572-577.
42. Brown RI, Cooper TG. Ticlopidine-carbamazepine interaction in a coronary stent patient. Can J Cardiol. 1997;13:853-854.
43. Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther. 1987;41: 358-362.
44. Yao SK, Ober JC, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM, Willerson JT. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol. 1994; 267:H488-H493.
45. Herbert JM, Bernat A, Sainte-Marie M, Dol F, Rinaldi M. Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit. Thromb Haemost. 1993; 69:268-271.
46. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial: the Studio della Ticlopidina nell'Angina Instabile Group. Circulation. 1990;82:17-26.
47. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
48. Leon M, Baim D, Popma J, Gordon P, Cutlip D, Ho K, Giambartolomei A, Diver D, Lasorda D, Williams D, Pocock S, Kuntz R. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665-1671.
49. Bertrand M, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden E. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation. 1998; 98:1597-1603.
50. Urban P, Macaya C, Rupprecht H, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998;98: 2126-2132.
51. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334: 1084-1089.
52. Berger PB, Bell MR, Grill DE, Melby S, Holmes DR Jr. Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). Am J Cardiol. 1998;81:713-718.
53. Kastrati A, Schuhlen H, Hausleiter J, Walter H, Zitzmann-Roth E, Hadamitzky M, Elezi S, Ulm K, Dirschinger J, Neumann FJ, Schomig A. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation. 1997;96:462-467.
54. Schomig A, Neumann FJ, Walter H, Schuhlen H, Hadamitzky M, Zitzmann-Roth EM, Dirschinger J, Hausleiter J, Blasini R, Schmitt C, Alt E, Kastrati A. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol. 1997;29:28-34.
55. Madan M, Marquis J, May M, Laramee L, Leddy D, O'Brien E, Williams W, Higginson L, Jelley J, Reid F, Johansen H, Labinaz M. Coronary stenting in unstable angina: early and late clinical outcomes. Can J Cardiol. 1998;14:1109-1114.
56. Gawaz M, Neumann FJ, Ott I, May A, Rudiger S, Schomig A. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart. 1996;76:166-172.
57. van de Loo A, Nauck M, Noory E, Just H, Wollschlager H. Enhancement of platelet inhibition of ticlopidine plus aspirin vs aspirin alone given prior to elective PTCA. Eur Heart J. 1998;19:96-102.
58. Steinhubl S, Lauer M, Mukherjee D, Moliterno D, Lincoff A, Ellis S, Topol E. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol. 1998;32:1366-1370.
59. Makkar R, Eigler N, Kaul S, Frimerman A, Nakamura M, Shah P, Forrester J, Herbert J, Litvack F. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J. 1998;19:1538-1546.
60. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, Vanhove P. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med. 1989;114:84-91.
61. Bergqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg. 1995;10:69-76.
62. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs: Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med. 1997;337:1726-1731.
63. Castelli P, Basellini A, Agus GB, Ippolito E, Pogliani EM, Colombi M, Gianese F, Scatigna M. Thrombosis prevention with ticlopidine after femoropopliteal thromboendarterectomy. Int Surg. 1986;71:252-255.
64. Hiatt WR. Current and future drug therapies for claudication. Vasc Med. 1997;2:257-262.
65. Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost. 1989;62:681-685.
66. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227:301-308.